Kmart pharmacists let Medicare beneficiaries use coupons for brand-name drugs rather than generics, the $1.4 M suit alleges.» Read More
Amgen has won federal approval for the second medicine in a new class of pricey biotech drugs that reduce artery-clogging cholesterol.
After Regeneron and Sanofi got FDA approval for their cholesterol drug last month, today is Amgen's turn. CNBC's Meg Tirrell reports.
The Ice Bucket Challenge is back, even if it's not nearly as big as last year.
A series of new studies out this week shows solid progress toward a flu vaccine in a pill and a so-called universal flu vaccine. NBC News reports.
CNBC's Meg Tirrell reports why investors are worried about the 14-percent pullback in biotech within the past month.
A female libido drug Addyi has been approval. Does that mean feminine versions of those classic Viagra ads? Probably not. Here's why.
The cholesterol drug space is set to get more crowded, and "Fast Money" traders believe one biotech company should benefit most.
Barbara Ryan, Clermont Partners, discusses Valeant nearing deal to buy Sprout Pharma and what consumers can expect when the "female" Viagra pill hits the market. CNBC's Meg Tirrell adds insight.
Valeant is buying the company that just won approval to sell "female Viagra."
GlaxoSmithKline shares jumped 3 percent after the U.K.-listed pharmaceutical giant reported second-quarter earnings per share that were slightly higher than forecast on Wednesday.
The CEO of German drugmaker Bayer has quashed any talk of acquiring its competitor Syngenta, which is being pursued by U.S. firm Monsanto.
Gilead blew past top and bottom line expectations on the strength of strong sales for its hepatitis C treatments.
Barbara Ryan, Clermont Partners, breaks down Pfizer and Merck's quarterly results and shares her outlook on the pharmaceutical sector.
Teva will acquire Allergan's generics unit for $40.5 billion. CNBC's Meg Tirrell takes a look at other potential M&A action in the space.
Chart analyst John Kosar shows how investors can profit from the pullback in oil prices.
Allergan chief Brent Saunders says the sale of its generics business would allow the company to double down on its higher margin branded business.
One large pharmacy benefit manager warns that costs from new PCSK9 drugs could reach as high as $150 billion annually.
CNBC's Meg Tirrell reports on the FDA approving Regeneron's cholesterol drug Praluent.
Shares of Regeneron were down about 3 percent after the FDA approved Regeneron's cholesterol-lowering drug Praluent on Friday.
CNBC's Meg Tirrell reports on a Glaxo Malaria vaccine for use in Sub-Saharan Africa as it seeks the final steps to approval.
Get the best of CNBC in your inbox